Syndax Pharmaceuticals, Inc.(SNDX)

$19.84—

Chart

Syndax Pharmaceuticals, Inc.(SNDX)

NASDAQ

$19.84—

Chart Studio

SNDX(SNDX)

SNDX

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.51

Nov 2, 2026 · Reports after close

Revenue Estimate

$85M

FY2028E EPS$0.55

FY2029E EPS$2.04

Analyst Sentiment

Wall St. Consensus

Buy

21 analysts·High coverage

Score

20 Buy (95%)1 Hold (5%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

2095%

Hold

15%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$31.00

+56.3%

Consensus

$37.50

+89.0%

Bull

$46.00

+131.9%

12-Month Target Range21 analysts

$31.00$37.50$46.00

Current $19.84Consensus

Current Price

$19.84

Upside to Consensus

$17.66

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+47.00%

EPS—

FY2028

Rev+37.96%

EPS—

FY2029

Rev+34.05%

EPS+272.96%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$327M	$481M	$663M	$889M	$1.08B
Low	$309M	$433M	$532M	$774M	$942M
High	$352M	$575M	$845M	$1.08B	$1.32B
EBITDA Avg	$13M	$18M	$26M	$34M	$42M
Low	$12M	$17M	$20M	$30M	$36M
High	$14M	$22M	$32M	$42M	$51M
EBIT Avg	$13M	$18M	$25M	$34M	$42M
Low	$12M	$17M	$20M	$30M	$36M
High	$14M	$22M	$32M	$42M	$51M
Net Income Avg	$-163M	$-31M	$93M	$176M	$254M
Low	$-218M	$-171M	$-95M	$147M	$211M
High	$-115M	$56M	$139M	$226M	$325M
EPS Avg	$-1.89	$-0.67	$0.55	$2.04	$2.93
Low	$-2.52	$-1.97	$-1.09	$1.69	$2.43
High	$-1.33	$0.64	$1.61	$2.61	$3.75
Analysts (Rev / EPS)	7 / 7	9 / 8	10 / 6	5 / 3	5 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$87M	$102M	$73M	$73M	$73M	$73M
Low	$80M	$88M	$66M	$66M	$66M	$66M
High	$93M	$115M	$83M	$83M	$83M	$83M
EBITDA Avg	$3M	$4M	$3M	$3M	$3M	$3M
Low	$3M	$3M	$3M	$3M	$3M	$3M
High	$4M	$4M	$3M	$3M	$3M	$3M
EBIT Avg	$3M	$4M	$3M	$3M	$3M	$3M
Low	$3M	$3M	$3M	$3M	$3M	$3M
High	$4M	$4M	$3M	$3M	$3M	$3M
Net Income Avg	$-39M	$-36M	$-6M	$-16M	$-8M	$-14M
Low	$-58M	$-70M	$-8M	$-18M	$-9M	$-16M
High	$-21M	$-17M	$-6M	$-14M	$-7M	$-12M
EPS Avg	$-0.44	$-0.40	$-0.07	$-0.17	$-0.09	$-0.15
Low	$-0.65	$-0.79	$-0.08	$-0.21	$-0.10	$-0.18
High	$-0.23	$-0.19	$-0.06	$-0.15	$-0.08	$-0.13
Analysts (Rev / EPS)	6 / 8	6 / 7	3 / 2	3 / 2	3 / 2	3 / 5

Earnings Surprises

Recent Analyst Actions

Aug 5, 2026H.C. Wainwright

Syndax price target lowered to $38 from $40 at H.C. Wainwright

Target:$38.00

+99.2%from $19.08

Jun 12, 2026Guggenheim

Syndax price target lowered to $31 from $34 at Guggenheim

Target:$31.00

+73.1%from $17.91

Jun 3, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Target:$40.00

+117.5%from $18.39

May 4, 2026Stifel Nicolaus

Syndax price target raised to $46 from $45 at Stifel

Target:$46.00

+140.7%from $19.11

May 1, 2026Barclays

Syndax price target raised to $37 from $35 at Barclays

Target:$37.00

+72.7%from $21.43

Feb 27, 2026Stifel Nicolaus

Syndax Pharmaceuticals (SNDX) PT Raised to $45 at Stifel

Target:$45.00

+107.3%from $21.71

Nov 24, 2025Barclays

Syndax price target raised to $35 from $22 at Barclays

Target:$35.00

+100.7%from $17.44

Nov 4, 2025UBS

Syndax price target raised to $38 from $35 at UBS

Target:$38.00

+176.2%from $13.76

Nov 4, 2025Barclays

Syndax price target raised to $22 from $19 at Barclays

Target:$22.00

+59.9%from $13.76

Sep 10, 2025Stifel Nicolaus

Syndax resumed with a Buy at Stifel

Target:$44.00

+179.7%from $15.73

Jul 15, 2025UBS

Syndax price target lowered to $35 from $37 at UBS

Target:$35.00

+257.3%from $9.79

Jul 10, 2025Goldman Sachs

Syndax initiated with a Buy at Goldman Sachs

Target:$18.00

+83.3%from $9.82

Nov 13, 2024Scotiabank

Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank

Target:$18.00

-10.2%from $20.04

Oct 24, 2024UBS

UBS Starts Syndax Pharmaceuticals (SNDX) at Buy

Target:$37.00

+99.6%from $18.54

Aug 15, 2024Citigroup

Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi

Target:$34.00

+69.2%from $20.09

Aug 15, 2024Bank of America Securities

Syndax price target raised to $31 from $30 at BofA

Target:$31.00

+58.3%from $19.58

Aug 15, 2024Barclays

Syndax price target raised to $33 from $32 at Barclays

Target:$33.00

+68.5%from $19.58

Jul 30, 2024Bank of America Securities

Syndax Pharmaceuticals (SNDX) PT Lowered to $30 at BofA Securities

Target:$30.00

+36.4%from $21.99

Jun 28, 2024Jefferies

Jefferies Starts Syndax Pharmaceuticals (SNDX) at Buy

Target:$37.00

+82.1%from $20.32

May 9, 2024Stifel Nicolaus

Syndax Pharmaceuticals (SNDX) PT Raised to $40 at Stifel

Target:$40.00

+78.7%from $22.38

Jan 3, 2023J.P. Morgan

JP Morgan Initiates Coverage On Syndax Pharmaceuticals with Overweight Rating, Announces Price Target of $41

Target:$41.00

+55.7%from $26.32

Dec 12, 2022Goldman Sachs

Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $39

Target:$39.00

+66.7%from $23.39

Dec 12, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $33

Target:$33.00

+59.9%from $20.64

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance